Accurate results
for patient care
Laboratory medicine and in vitro diagnostics
JCTLM Database: higher-order reference materials, methods and services
Details : C20RMP7 - ID-LC-MS/MS-based reference measurement procedure for the quantification of carbamazepine in human serum and plasma
| Type (acronym) | rmp |
|---|---|
| Type | reference measurement procedure |
| Unique Nomination Number | C20RMP7 |
| Analyte Name | carbamazepine |
| Method capable of Traceability of Analyte to SI or Defined Procedure | yes |
| Applicable Matrices | human serum and plasma; fresh or frozen |
| Name | ID-LC-MS/MS-based reference measurement procedure for the quantification of carbamazepine in human serum and plasma |
| Organization that developed Validated Method | This reference measurement procedure was developed and validated by the laboratory of Dr. Risch Ostschweiz AG in Buchs SG, Switzerland in collaboration with Roche Diagnostics GmbH in Penzberg, Germany |
| Measurement Techniques Used | Isotope dilution mass spectrometry |
| Quantity | Mass concentration |
| From (0) | 0.8 |
| To (0) | 18 |
| Unit (0) | µg/mL |
| From (1) | 2 |
| To (1) | 2.4 |
| Unit (1) | % |
| Level of Confidence (%) | 95% |
| Comments on Uncertainty Range | The lowest expected measurement uncertainty of 2.0 % is at the mass concentration of 1.20 µg/mL, where n = 6 measurements. The highest expected measurement uncertainty of 2.4 % is at the mass concentration of 16.0 µg/mL, where n = 6 measurements |
| Peer Reviewed Publication | An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for the quantification of carbamazepine in human serum and plasma, Taibon J. et al, Clinical Chemisty and Laboratory Medicine 2023 Dec. 13 |
| Comments to be published via JCTLM DB | This reference measurement procedure was developed and validated by the laboratory of Dr. Risch Ostschweiz AG in Buchs SG, Switzerland in collaboration with Roche Diagnostics GmbH in Penzberg, Germany |
| Hyperlink to Final Report of extent of Equivalence Studies among | A method comparsion study between the candidate RMP and the JCTLM listed RMP C14RMP5 was performed. See Supplemental material 1 of the CCLM 2023 61(11) method publication cited above. |
| Analyte Category Name | Drugs |
| Measurement principle/technique | Isotope dilution mass spectrometry |